Company Filing History:
Years Active: 2013-2014
Title: David Weaver: Innovator in Biotechnology
Introduction
David Weaver is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target epidermal growth factor receptors. With a total of 2 patents, his work has the potential to impact cancer treatment and therapeutic applications.
Latest Patents
David Weaver's latest patents include innovative humanized anti-epidermal growth factor receptor antibodies. These antibodies exhibit favorable binding activity, with binding affinities of 6.13×10 mol/L and 5.09×10 mol/L, respectively. They are designed to inhibit the growth and migration of tumor cells, showcasing their potential in cancer therapy. The patents also detail the preparation methods and various uses of these antibodies, highlighting their significance in medical research.
Career Highlights
Throughout his career, David has worked with notable companies in the biotechnology sector. He has been associated with Guangzhou Yunyuan Biotech Co., Ltd. and Hefei Tairui Biotechnology Co., Ltd. His experience in these organizations has contributed to his expertise in developing cutting-edge biotechnological solutions.
Collaborations
David Weaver has collaborated with several professionals in his field, including Michael Rynkiewicz and Cheng Cao. These partnerships have fostered innovation and advancement in his research endeavors.
Conclusion
David Weaver stands out as an influential inventor in the biotechnology industry, with a focus on developing effective cancer therapies. His contributions through patents and collaborations continue to shape the future of medical science.